Skip to main content

Advertisement

SpringerLink
Log in

Cost-Utility Estimation of Surgical Treatment of Pancreatic Carcinoma Aimed at Cure

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Little is reported on costs for radical tumor resections of pancreatic carcinoma in relationship to adjusted quality of life survival postoperatively. Therefore, the aim of the present study was to estimate the cost utility of surgical treatment aimed at cure.

Methods

A population-based cohort of patients with exocrine or ampullary pancreatic adenocarcinoma resected for cure in Gothenburg University Hospitals during 1998–2005 were evaluated retrospectively (n = 139). Total inpatient and outpatient healthcare costs were available for 103 patients, and health-related quality of life (HRQL) (based on the SF-36 Health Survey) were assessed preoperatively and postoperataively in 119 patients. Survival and utility index (SF-36-6D) across 5 years of postoperative follow-up were used to achieve quality adjusted life years.

Results

Mean survival after resection was 977 days for patients with exocrine pancreatic carcinoma, with expected differences among subgroups as related to disease stage (p < 0.01), in agreement with international reports. The HRQL index was 0.65 ± 0.06 preoperatively, 0.63 ± 0.04 early postoperatively (<1 year) and 0.69 ± 0.06 at long-term follow-up (1–5 years) compared to 0.77 ± 0.02 in age-matched healthy reference individuals from the Swedish population (p < 0.05). Total lifetime costs for treatments including surgery and adjuvant chemotherapy were €39,000 per patient, with a mean of 1.13 (95% Confidence Interval [CI] 0.93–1.40) QALYs across 5 years follow-up. The cost per QALY was €35,000 (95% CI €28,026–€41,947).

Conclusions

Resection aimed at cure of pancreatic exocrine ductal carcinoma provided costs for one quality adjusted year of survival comparable to other complex surgical treatments within cost limits regarded as reasonable to bear by the Swedish health care system, as well as in several other Western countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  2. Bramhall SR, Allum WH, Jones AG et al (1995) Treatment and survival in 13, 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82:111–115

    Article  CAS  PubMed  Google Scholar 

  3. Buchler MW, Wagner M, Schmied BM et al (2003) Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 138:1310–1314 discussion 1315

    Article  PubMed  Google Scholar 

  4. Lillemoe KD, Yeo CJ, Cameron JL (2000) Pancreatic cancer: state-of-the-art care. CA Cancer J Clin 50:241–268

    Article  CAS  PubMed  Google Scholar 

  5. Diener MK, Heukaufer C, Schwarzer G et al (2008) Pancreaticoduodenectomy (classic Whipple) versus pylorus-preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2:CD006053

    PubMed  Google Scholar 

  6. Trede M, Schwall G, Saeger HD (1990) Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 211:447–458

    Article  CAS  PubMed  Google Scholar 

  7. Nagakawa T, Sanada H, Inagaki M et al (2004) Long-term survivors after resection of carcinoma of the head of the pancreas: significance of histologically curative resection. J Hepatobiliary Pancreat Surg 11:402–408

    Article  PubMed  Google Scholar 

  8. Carpelan-Holmstrom M, Nordling S, Pukkala E et al (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54:385–387

    Article  CAS  PubMed  Google Scholar 

  9. Yeo CJ, Sohn TA, Cameron JL et al (1998) Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 227:821–831

    Article  CAS  PubMed  Google Scholar 

  10. Cleary SP, Gryfe R, Guindi M et al (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731

    Article  PubMed  Google Scholar 

  11. Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223:273–279

    Article  CAS  PubMed  Google Scholar 

  12. Ferrone CR, Brennan MF, Gonen M et al (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12:701–706

    Article  PubMed  Google Scholar 

  13. Kazanjian KK, Hines OJ, Duffy JP et al (2008) Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg 143:1166–1171

    Article  PubMed  Google Scholar 

  14. Andersson R, Vagianos C, Williamson R (2004) Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 6:5–12

    CAS  Google Scholar 

  15. Du W, Touchette D, Vaitkevicius VK et al (2000) Cost analysis of pancreatic carcinoma treatment. Cancer 89:1917–1924

    Article  CAS  PubMed  Google Scholar 

  16. Hjelmgren J, Ceberg J, Persson U et al (2003) The cost of treating pancreatic cancer—a cohort study based on patients’ records from four hospitals in Sweden. Acta Oncol 42:218–226

    Article  PubMed  Google Scholar 

  17. Huang JJ, Yeo CJ, Sohn TA et al (2000) Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg 231:890–898

    Article  CAS  PubMed  Google Scholar 

  18. Kokoska ER, Stapleton DR, Virgo KS et al (1998) Quality of life measurements do not support palliative pancreatic cancer treatments. Int J Oncol 13:1323–1329

    CAS  PubMed  Google Scholar 

  19. Crippa S, Dominguez I, Rodriguez JR et al (2008) Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg 12:783–793 (discussion 793–784)

    Article  PubMed  Google Scholar 

  20. Schniewind B, Bestmann B, Kurdow R et al (2006) Bypass surgery versus palliative pancreaticoduodenectomy in patients with advanced ductal adenocarcinoma of the pancreatic head, with an emphasis on quality of life analyses. Ann Surg Oncol 13:1403–1411

    Article  CAS  PubMed  Google Scholar 

  21. Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB et al (2005) Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 92:471–477

    Article  CAS  PubMed  Google Scholar 

  22. Schniewind B, Bestmann B, Henne-Bruns D et al (2006) Quality of life after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head. Br J Surg 93:1099–1107

    Article  CAS  PubMed  Google Scholar 

  23. Esposito I, Friess H, Buchler MW (2001) Carcinogenesis of cancer of the papilla and ampulla: pathophysiological facts and molecular biological mechanisms. Langenbecks Arch Surg 386:163–171

    Article  CAS  PubMed  Google Scholar 

  24. Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13

    Article  PubMed  Google Scholar 

  25. Wente MN, Bassi C, Dervenis C et al (2007) Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 142:761–768

    Article  PubMed  Google Scholar 

  26. Wente MN, Veit JA, Bassi C et al (2007) Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 142:20–25

    Article  PubMed  Google Scholar 

  27. Raymond WA, Leong AS (1989) Immunoperoxidase staining in the detection of lymph node metastases in stage I breast cancer. Pathology 21:11–15

    Article  CAS  PubMed  Google Scholar 

  28. Amemiya K, Suzuki J, Kimura M (1986) Mechanism of action of pronase on chronic proliferative inflammation including granuloma angiogenesis in mice. Nippon Yakurigaku Zasshi 88:279–288

    Article  CAS  PubMed  Google Scholar 

  29. Hosch SB, Knoefel WT, Metz S et al (1997) Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. Pancreas 15:154–159

    Article  CAS  PubMed  Google Scholar 

  30. Hosch S, Kraus J, Scheunemann P et al (2000) Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res 60:6836–6840

    CAS  PubMed  Google Scholar 

  31. Ware JE Jr, Snow KK, Kolinski M et al (1993) SF-36 Health survey manual and interpretation guide. The Health Institute, New England Medical Center, Boston

    Google Scholar 

  32. Sullivan M, Karlsson J, Ware JE Jr (1995) The Swedish SF-36 Health Survey-I. Evaluation of data quality, scaling assumptions, reliability, and construct validity across general populations in Sweden. Soc Sci Med 41:1349–1358

    Article  CAS  PubMed  Google Scholar 

  33. Brazier J, Usherwood T, Harper R et al (1998) Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 51:1115–1128

    Article  CAS  PubMed  Google Scholar 

  34. Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21:271–292

    Article  PubMed  Google Scholar 

  35. Kaplan RM (2002) Utility assessment for estimating quality-adjusted life years. In: Sloan FA (ed) Valuing health care. Costs, benefits, and effectiveness of pharmaceutical and other medical technologies. Cambridge University Press, New York

    Google Scholar 

  36. Billingham LJ, Abrams KR (2002) Simultaneous analysis of quality of life and survival data. Stat Methods Med Res 11:25–48

    Article  CAS  PubMed  Google Scholar 

  37. Rindi G, Kloppel G (2004) Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 80(suppl 1):12–15

    Article  CAS  PubMed  Google Scholar 

  38. Winter JM, Cameron JL, Campbell KA et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10:1199–1210 (discussion 1210–1191)

    Article  PubMed  Google Scholar 

  39. Benassai G, Mastrorilli M, Mosella F et al (1999) Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res 18:23–28

    CAS  PubMed  Google Scholar 

  40. Talamonti MS, Small W Jr, Mulcahy MF et al (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13:150–158

    Article  PubMed  Google Scholar 

  41. Kurahara H, Takao S, Maemura K et al (2007) Impact of lymph node micrometastasis in patients with pancreatic head cancer. World J Surg 31:483–490 (discussion 491–482)

    Article  PubMed  Google Scholar 

  42. Hosch SB, Steffani KD, Scheunemann P et al (2002) Micrometastases from HBP malignancies and metastatic cancer. J Hepatobiliary Pancreat Surg 9:583–591

    Article  PubMed  Google Scholar 

  43. Tseng JF, Pisters PW, Lee JE et al (2007) The learning curve in pancreatic surgery. Surgery 141:694–701

    Article  PubMed  Google Scholar 

  44. Esposito I, Kleeff J, Bergmann F et al (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660

    Article  PubMed  Google Scholar 

  45. Tappenden P, Chilcott J, Ward S et al (2006) Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 42:2867–2875

    Article  PubMed  Google Scholar 

  46. Hwang JS, Tsauo JY, Wang JD (1996) Estimation of expected quality adjusted survival by cross-sectional survey. Stat Med 15:93–102

    Article  CAS  PubMed  Google Scholar 

  47. Matthews JN, Altman DG, Campbell MJ et al (1990) Analysis of serial measurements in medical research. BMJ 300:230–235

    Article  CAS  PubMed  Google Scholar 

  48. Earle CC, Chapman RH, Baker CS et al (2000) Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18:3302–3317

    CAS  PubMed  Google Scholar 

  49. Kontodimopoulos N, Niakas D (2008) An estimate of lifelong costs and QALYs in renal replacement therapy based on patients’ life expectancy. Health Policy 86:85–96

    PubMed  Google Scholar 

  50. Longworth L, Young T, Buxton MJ et al (2003) Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl 9:1295–1307

    Article  PubMed  Google Scholar 

  51. Clegg AJ, Colquitt J, Sidhu MK et al (2002) The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol Assess 6:1–153

    CAS  PubMed  Google Scholar 

  52. Henriksson M, Lundgren F, Carlsson P (2008) Cost-effectiveness of endarterectomy in patients with asymptomatic carotid artery stenosis. Br J Surg 95:714–720

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported in part by grants from the Assar Gabrielsson Foundation (AB Volvo), the Gothenburg Medical Society, the Swedish government (LUA-ALF), the Swedish Cancer Society (2014), and the Swedish Research Council (08712).

Author information

Authors and Affiliations

  1. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, 413 45, Gothenburg, Sweden

    David Ljungman, Kent Lundholm & Anders Hyltander

Authors
  1. David Ljungman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kent Lundholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anders Hyltander
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anders Hyltander.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ljungman, D., Lundholm, K. & Hyltander, A. Cost-Utility Estimation of Surgical Treatment of Pancreatic Carcinoma Aimed at Cure. World J Surg 35, 662–670 (2011). https://doi.org/10.1007/s00268-010-0883-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-010-0883-8

Keywords

Search

Navigation